Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
Grant of First Method of Use Patent Adds New Pillar to Grace’s Multi-layered Intellectual Property and Potential Market Exclusivity Protection...
Brain
Bio Protocol Raises $6.9M to Launch AI-Native Decentralized Science Platform for Biotech Funding & Drug Discovery
Bio Protocol enables researchers and patients to launch BioAgents - autonomous AI co-scientists that generate hypotheses, fund experiments and monetize biotech...
Linus Health’s AI-Driven Voice Analysis Technology Recognized in Gartner® Hype Cycle™ for Digital Care Delivery, 2025
BOSTON, Sept. 17, 2025 /PRNewswire/ -- Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and...
ALLT.AI unveils the next generation of Large Language Models (LLMs) driven by the remarkable power and efficiency of the human brain
Translating decades of clinical neuroscience research into next-generation AI—ALLT.AI harnesses key data from damaged brains to create radically more efficient...
Aoki Games & Gala 2025 Returns to Las Vegas Sunday, September 21
Live performance, visionary conversations, and a tribute to Ray Kurzweil unite in support of brain health and innovation. LAS VEGAS,...
Apollo Biowellness, Inc., to Merge with Revive Regenerative, Inc.
North Bergen, New Jersey--(Newsfile Corp. - September 17, 2025) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company") is pleased to...
NovalGen to Begin World’s First Clinical Trial for a Self-Regulating Immunotherapy
LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The world’s first therapeutic drug to be equipped with NovalGen’s pioneering AutoRegulation (AR)...
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA ApprovalKANSAS CITY, Kan., Sept. 17, 2025 (GLOBE NEWSWIRE)...
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) servicesMALVERN, Pa., Sept. 17, 2025...
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to...
Omni-Biotic US Expands Into Children’s Gut Health With Two New Probiotics: AB 10 Kids and Stress Release Kids
NEW YORK CITY, NEW YORK / ACCESS Newswire / September 17, 2025 / Omni-Biotic US, the company that introduced Europe's...
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational...
AskBio Announces Completion of Enrollment in Phase 1 Clinical Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)
Research Triangle Park, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Final participant randomized to complete enrollment in Phase 1 clinical...
CervoMed Highlights Neflamapimod’s Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for...
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apneaNEW...
Hemostemix to Present at Life Science Investor Forum
Calgary, Alberta--(Newsfile Corp. - September 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
Optigenex Inc. Reports Positive Results in a Group of Human Subjects with Normal Cognitive Function, in a Double-Blind, Cross Over, Placebo Controlled, Randomized Cognitive Study with ac-11(R)
Study Sponsored by Optigenex Inc. and conducted by the University of Northern Arizona led by Doctor Oneil Guthrie, demonstrates significant...
Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina
Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
Arterial HealthTech CONNEQT Declares the Future of Heart Health Has Arrived
NAPERVILLE, Ill., Sept. 16, 2025 /PRNewswire/ -- Apple Watch just delivered the alert. The Pulse from CONNEQT Health delivers the answer....
Trinity Capital Inc. Provides Up to $50 Million in Growth Funding to Nalu Medical, Supporting Continued Commercial Momentum
PHOENIX, Sept. 16, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the...